MDCLF (Medincell) Asset Impairment Charge: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCLF Medincell SA MDCLF
77 GF Score
Price $34.39
GF Value $27.51
! 5 Warning Signs
View Full Analysis

What is Medincell Asset Impairment Charge?

Medincell MDCLF +393.00% 77 Asset Impairment Charge is $0.00 Mil as of Mar. 2026. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review.

Medincell's Asset Impairment Charge for the six months ended in Mar. 2026 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Medincell Asset Impairment Charge Related Terms

Medincell Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Medincell's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell Asset Impairment Charge Chart

Medincell Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MDCLF
77GF Score
Medincell SA MDCLF
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Asset Impairment Charge of $0.00 Mil mean?
Medincell (MDCLF) has a Asset Impairment Charge of $0.00 Mil as of Mar. 2026.
Is Medincell's Asset Impairment Charge too high?
Medincell's current Asset Impairment Charge is $0.00 Mil. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's Asset Impairment Charge compare to VRTX and REGN?
Medincell's Asset Impairment Charge of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Medincell's current Asset Impairment Charge is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current Asset Impairment Charge of $0.00 Mil. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current Asset Impairment Charge is $0.00 Mil. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Medincell (MDCLF), the current Asset Impairment Charge is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (MDCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.

Key valuation signals for MDCLF:

  • Asset Impairment Charge: $0.00 Mil
  • GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for MDCLF

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.39
Price
$27.51
GF Value